Ferring Receives U.S. FDA Approval for REBYOTA™ – A Novel First-in-Class Microbiota-Based Live Biotherapeutic
October 6, 2022
Seres Therapeutics Announces FDA acceptance of Biologics License Application For Ser-109
View the full article at Ferringusa.com.
Saint-Prex, Switzerland and Parsippany, NJ, USA – 30 November, 2022 – Ferring Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) approved REBYOTA™ (fecal microbiota, live-jslm), a novel first-in-class microbiota-based live biotherapeutic indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI.